Six Breakthrough Immune Cell Therapies Achieve Remarkable Response Rates Across Multiple Cancers Including Lung and Pancreatic Cancer, with Some Patients Achieving Complete Metastatic Clearance
Grit Biotherapeutics
Developer of Immunotherapy Drugs for Solid Tumors
Cancer, like an ever-evolving "life predator," with its complex mutation mechanisms and diverse pathological types, has always been a challenging problem in the medical field.
In recent years, precision medical technologies centered on immune cell therapy are rewriting the landscape of cancer treatment with unprecedented momentum.CAR-T, TCR-T, TIL, CAR-NK, and other six cutting-edge therapies have successively achieved breakthroughs, demonstrating exciting potential in the treatment of hematologic malignancies and solid tumors. The following focuses on the six major immune cell therapies that are highly anticipated in 2025, analyzing their groundbreaking progress and clinical value, with the aim of helping more patients regain confidence and embrace treatment positively.
1. CAR-T Therapy: A "Cure-Level" Breakthrough for Multiple Myeloma
OriCAR-017 is a novel CAR-T therapy targeting the GPRC5D antigen, which has received dual IND approval from both China and the United States. The long-term follow-up data from the Phase 1 clinical trial, published in the *Journal of Clinical Oncology*, is nothing short of impressive:
Peak Efficacy:The overall response rate (ORR) reached 100% in 10 enrolled patients with relapsed/refractory multiple myeloma (RR MM) (n=10), and the stringent complete response rate (sCR) was as high as 80%; the minimal residual disease (MRD) negativity rate reached 100% on Day 28 of treatment and was further confirmed to be 100% negative at Month 3.
Survival Duration:The median progression-free survival (mPFS) was 11.37 months, with a favorable safety profile, offering deep and durable relief hope for patients with advanced myeloma.
▲Screenshot source: "ASCO Publications"
2. TCR-T Therapy: The "Precision Sniper" for Lung Cancer Metastases
"OncoLOGY LETTERS" reported a clinical study (NCT02457650) on "the application of NY-ESO-1-specific TCR-T cells in the treatment of advanced non-small cell lung cancer (NSCLC)," with remarkable data:
Reverse Advanced Stage ConditionA 44-year-old HLA-A2 positive lung adenocarcinoma patient, after failing multiple lines of treatment, achieved partial response (PR) four months after receiving NYESO1 TCR-T therapy. The primary lung lesion decreased from 95×86×54mm to 64×44×54mm, the liver metastases reduced by nearly 50%, pleural effusion was completely absorbed, and the Karnofsky Performance Score (KPS) improved from 50 to 90, with significant symptom relief.
Highlights of the Mechanism:Targeting the tumor-specific antigen NYESO1, it has potential therapeutic value for 11.8%~21% of NSCLC patients expressing this antigen.
'%20fill='%23FFFFFF'%3E%3Crect%20x='249'%20y='126'%20width='1'%20height='1'%3E%3C/rect%3E%3C/g%3E%3C/g%3E%3C/svg%3E)
▲Screenshot source: "OncologyLetters”
3. TIL Therapy: The "Rapid Elimination" Miracle for Cervical Cancer
Gravel Biotech DevelopmentGT316 is a CRISPR/Cas9-dualKO anti-exhaustion TIL therapy product.Data from the first-in-human trial (NCT06145802) presented at the 2025 AACR Annual Meeting showed:
Rapid Response: A refractory cervical cancer patient achieved complete remission (CR) just 4 weeks after infusion of GT316. The 24mm vaginal metastatic lesion present before treatment completely disappeared (100%) in the imaging examination at Week 38, demonstrating the rapid tumor-clearing ability of TIL therapy against solid tumors.
▲Screenshot source: "OncologyLetters"
4. NK Cell Combined Vaccine: "Three-Dimensional Strike" for Advanced Endometrial Cancer
The case of combination therapy reported in Cureus showed that the efficacy was comprehensively improved in a Stage IV endometrial cancer patient who adopted the regimen of "chemotherapy + WT1-DC vaccine + highly active NK cells."
Lesion Clearance:After 142 days of combination therapy, the lung metastases and peritoneal dissemination lesions completely disappeared, the liver metastases significantly shrank, and the primary tumor volume was markedly reduced.
Symptom Improvement:The basic absorption of ascites, significant reduction in carcinoembryonic antigen (CEA) and CA125 levels, and decreased abdominal circumference have provided a new treatment approach for patients who failed multiple lines of therapy.
5. CAR-NK Therapy: The "Survival Extender" for Pancreatic Cancer
The Journal of Cancer Research and Therapeutics once reported a classic case of significant lesion control using Robo1-specific chimeric antigen receptor natural killer cells (CAR-NK) for the treatment of metastatic pancreatic ductal adenocarcinoma. ThisA 46-Year-Old Patient with Stage IV Pancreatic Ductal Adenocarcinoma Refused Chemotherapy and Received Robo1-CAR-NK Therapy:
Lesion Control:No progression of the primary pancreatic lesion and liver metastases within 5 months, with the patient's overall survival (OS) exceeding 8 months (traditional OS for advanced pancreatic cancer is only 3-6 months), demonstrating the salvage value of NK cells for patients intolerant to chemotherapy.
▲Screenshot source: "JCRT"
6. γδT Cell Therapy: The "Long-term Controller" for Renal Cell Carcinoma
A I/II phase trial reported in "Cancer Immunology and Immunotherapy" showed that γδT cell therapy had significant efficacy for advanced metastatic renal cell carcinoma:
Complete Remission Case:One CasePatient TR05 Achieves Complete Disappearance of Lung Metastases After 7 Months of γδT Cell Therapy, Remains Cancer-Free for Over 36 Months. Within 3 Months of Treatment, Macroscopic Clearance of Two Metastatic Lesions Was Observed. This Demonstrates the Potential of γδT Cell Therapy to Induce Tumor Regression and Achieve Long-Term Disease Control in Advanced Renal Cell Carcinoma.
Editor's Note
From hematological tumors to solid tumors, from short-term remission to long-term cure, six major immunocyte therapies are redefining the boundaries of cancer treatment with their characteristics of "precise recognition, efficient killing, low toxicity, and safety." These breakthroughs represent not only a leap in scientific research data but also the hope of a new lease on life for countless patients.
In the future, with the continuous optimization of gene editing and combination therapy strategies, immune cell therapy is expected to achieve the leap "from effective to curative" in more cancer types. Patients are advised to choose personalized precision treatment plans under the guidance of professional doctors, combining genetic testing and condition assessment. Patients who wish to identify their own targets or seek help from novel anti-cancer therapies can contact us for an initial evaluation or further details.
References
[1] Huang H, et al. OriCAR-017 in relapsed/refractory multiple myeloma: Long term follow-up. ASCO 2024.
[2] Xia Y, et al. NY-ESO-1 TCR-T for NSCLC. Oncology Letters, 2018.
[3] Nagai H, et al. NK cell + WT1-DC vaccine for ovarian cancer. Cureus, 2024.
[4] Li C, et al. Robo1-CAR-NK for pancreatic cancer. JCRT, 2020.
[5] Kobayashi H, et al. γδT cells for renal cell carcinoma.Cancer Immunol Immunother, 2011.
Disclaimer | This article aims to introduce the progress of medical research and cannot be used as a basis for patients to treat diseases. For medical and health guidance, please visit a regular hospital.
Source | ASCO Publications、OncologyLetters、JCRT`, owned by the original author, if we unintentionally infringe on intellectual property rights, please contact us for removal.`
About Us
Huamei Haolian possesses exceptional capabilities in integrating global medical resources, andInternational 8 renowned medical systems, spanning 41 specialties, with over 3,000 international expertsEstablish a cooperative relationship, official signing270 Top Tier-3 Hospitals in China，Jointly build an international multidisciplinary physical or network-based remote consultation center,Medical Service Network Reach1,312 tertiary hospitals in China, breaking down geographical and disciplinary barriers in medical services, presenting customers with full-scenario, customized healthcare solutions, and aiming to become the global leader in smart medical services, so that everyone can enjoy a healthy life.If you want to learn about the latest overseas research achievements, drugs, and treatment information for major and complex diseases, or urgently need professional medical guidance and medical resource对接services (such as consultations with experts in and outside China, seeking medical treatment abroad, and finding special drugs globally), follow the official account below or contact the editor.
More cutting-edge information and AI-driven digital healthcare services
☟Scan below, follow us☟